OMER earnings analysis
What we found in OMER's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q2 2026 showed strong commercial momentum, with YARTEMLEA net revenue rising to $28.5 million from $9.9 million in Q1 and operating cash flow turning positive at $4.1 million. Liquidity was $132.0 million at June 30, 2026, but the period also included a $60.2 million debt-repurchase cash outlay and an $11.5 million non-cash gain that limits the quality of reported earnings. The negative European CHMP opinion on narsoplimab and sensitivity of the 2029 Notes derivative to stock-price movements remain significant risks, while no numeric financial guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- YARTEMLEA revenue accelerated
- YARTEMLEA net revenue increased to $28.5 million from $9.9 million in Q1 2026, indicating strong sequential commercial-launch momentum.
- Operations generated positive cash
- Operating cash flow was positive at $4.1 million in Q2 2026, an improvement from negative operating cash flow in the prior periods referenced in the earnings materials.
- Liquidity remained substantial
- Cash, cash equivalents and short-term investments totaled $132.0 million as of June 30, 2026, providing liquidity to fund operations.
- Share repurchases continued
- The company repurchased 488,716 shares during Q2 at an average price of $11.70 per share; approximately $90.1 million remained available under the $100.0 million program as of August 12, 2026.
- Controls remained effective
- Management concluded disclosure controls were effective at the reasonable-assurance level as of June 30, 2026, with no material change in internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- European regulatory setback
- The negative CHMP opinion on narsoplimab in Europe represents a regulatory setback and could constrain the product's potential European commercialization opportunity; the filing materials identify the European regulatory outcome as a material headwind.
- Derivative valuation volatility
- A 20% increase or decrease in the company's stock price would produce an approximately $15.8 million change in the fair value of the 2029 Notes embedded derivative; the derivative's reported fair value ranged from $40.4 million to $71.0 million under the stated valuation range.
- Repurchase program risk
- The share repurchase program may increase stock-price volatility and can be suspended or terminated at any time; approximately $90.1 million remained available for repurchases as of August 12, 2026.
- Large debt-repurchase cash outlay
- The $60.2 million cash cost associated with debt repurchases reduced liquidity despite positive operating cash flow of $4.1 million in Q2 2026.
- Profit benefited from non-cash gain
- Reported earnings benefited from an $11.5 million non-cash gain, reducing the quality and sustainability of the quarter's reported profit.
What they reported.
What the company itself reported, taken out of the document.
- Segment
- YARTEMLEA net revenue: $28.5 million, compared with $9.9 million in Q1 2026; other segment revenue was not disclosed in the provided filing text.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects enrollment to begin in two YARTEMLEA studies by year-end 2026 and targets an OMS805 Phase 1b trial in late 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Omeros Corporation's Q1 2026 10-Q report shows a strong financial position, primarily driven by the launch of YARTEMLEA, which generated $9.9 million in revenue during its first reporting period. The company also posted…
- 10-K · March 31, 2026
- Omeros Corporation reported a significant turnaround in Q4 2025, highlighting the FDA approval of YARTEMLEA and a substantial sale of zaltenibart to Novo Nordisk, resulting in a net income boost. Although revenue…
- 10-Q · November 13, 2025
- Omeros Corporation reported no revenue for Q3 2025, while its diluted EPS of -0.34 exceeded expectations of -0.52. Notably, the company anticipates receiving $240 million from a transaction with Novo Nordisk to bolster…
- 10-Q · August 14, 2025
- Omeros Corporation's Q2 2025 results exhibited continued setbacks, including a reported EPS of -0.43 against a consensus estimate of -0.55, with no revenue reported for the quarter. The company is navigating through…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing OMER makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever